Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Previous Speakers

Xiaodong Wang

Xiaodong Wang

TESARO Inc USA

Fatah Kashanchi

Fatah Kashanchi

George Mason University USA

Ranendra N Saha

Ranendra N Saha

Birla Institute of Technology & Science Pilani UAE

Aleksander Mendyk

Aleksander Mendyk

Jagiellonian University Medical College Poland

Maligne Guillermo E

Maligne Guillermo E

Gador S.A Argentina

Sunil Kumar Dubey

Sunil Kumar Dubey

Birla Institute of Technology and Science-Pilani India

Heyam Saad Ali

Heyam Saad Ali

Dubai Pharmacy College UAE

Asmita Gajbhiye Patil

Asmita Gajbhiye Patil

Dr. Harisingh Gour Central University India

BABE 2019

About Bioavailability & Bioequivalence Conference

BABE 2019 CONGRESS

Its an enormous pleasure and feel respected to organize 10th World Congress on Bioavailability & Bioequivalence scheduled during April 08-10, 2019 at Abu Dhabi, UAE. The conference is mainly focussed on the theme of “The rationale of BA/BE studies for Pharmaceutical business and Public health”.

BABE 2019 is designed with the keynote sessions, session lectures, poster presentations, presentations from the young researchers, panel Discussions, and the B2B meetings with world-renowned speakers from the stream of clinical and pharmaceutical sciences. It provides the best platform for the researchers to the researchers all over globe to introduce themselves to the innovative world with their unique research. Its an open forum to discuss new researches and the challenges faced during the BA/BE studies, manufacturing the generic drugs and their effect on the public health.

Target audience:

  • CEOs, CROs, Directors, Managers and research associates
  • Academic professionals
  • Industrial Scientists
  • Regulatory and Clinical Scientists
  • Researchers, Education providers
  • Students and Postdoctoral Fellows
  • Pharmacists
  • Government Agencies
  • Medical Practitioners
  • Clinical Pharmacologists
  • Clinical Toxicologists
  • Molecular and Cellular Pharmacologists

Scientific Sessions/ Tracks For BABE 2019

Track 1: Bioavailability

The extent of a medication or other substance which enters the flow when brought into the body as can have a functioning impact. Bioavailability is a basic estimation device since it decides the right measurements for non-intravenous organization of a medication. In clinical research preliminaries, the bioavailability of a medication is a key factor to be estimated in Phase 1 and Phase 2 of clinical trials. Deciding the absolute bioavailability of a medication is done through a pharmacokinetic examine. The focus of the bioavailability studies is to find out the extent of dosage form influencing the performance of the drug and find out the extent and rate of absorption. Its is estimated by the pharmacodynamic parameters like Acute pharmacological effect and Clinical response.

  • Hepatic first-pass effect

  • Factors influencing bioavailability

  • Route of administration

  • Relative bioavailability

  • Absolute bioavailability

Track 2: Bioequivalence

Bioequivalence is a term in pharmacokinetics used to survey the normal in vivo organic equality of two exclusive arrangements of a medication. On the off chance that two items are said to be bioequivalent it implies that they would be relied upon to be, in every practical sense, the same. The objective of such examination is to assess the restorative similarity of tried medications (pharmaceutical counterparts or pharmaceutical choices). The significance of bioequivalence ponders is expanding likewise because of the huge development of the generation and utilization of non-specific item.

  • In vitro Bioequivalence

  • Clinical trial formulations

  • Therapeutic index

  • Generic drugs

  • Bioequivalence of endogenous substances

Track 3: Biosimilars

A biosimilar (otherwise called take after on biologic or ensuing section biologic) is a biologic therapeutic item which is very nearly an indistinguishable duplicate of a unique item that is made by an alternate company. Biosimilars are the duplicate products of the original products and they can be manufactured only when the patent of original products expired. Reference to the trailblazer item is a vital segment of the endorsement. Biosimilars treat probably the most genuine, perilous sicknesses and have the potential for genuine safe reactions and having low cost.

  • Biopharmaceuticals

  • Patent rights(Regulatory affairs)

  • Design for Biologics and Biosimilars

  • Biosimilars development

Track 4: Pharmacology

Pharmacology is a different teach in the health sciences. Pharmacology is the study of how drugs act on organic frameworks and how the body reacts to the medication. The investigation of pharmacology includes the sources, compound properties, organic impacts and remedial employments of medications. Drug store utilizes the information got from pharmacology to accomplish ideal restorative results through the suitable arrangement and administering of medicines. The two primary territories of pharmacology are pharmacodynamics and pharmacokinetics. Pharmacodynamics considers the impacts of a medication on organic frameworks, and Pharmacokinetics thinks about the impacts of natural frameworks on a medication.

  • Clinical pharmacology

  • Pharmacogenomics

  • Toxicology

  • Pharmacognosy

  • Posology

  • Pharmacotherapeutics

Track 5: Clinical research

Clinical researches are medical research studies involving individuals that aim to examine whether medications are safe also to know their mechanism. In clinical trials, healthy volunteers or patients or both involve in a trial to take part in the care and treatment. Clinical trials are carried out to answer specific questions about health and disease. Clinical trial is a systematic examination in individual subjects for assessing the safety & efficacy of any novel drug. Clinical trials are a set of tests in medical research also drug development so as to generate safety and efficacy information for health interventions in individual.

  • Preclinical trails

  • Phases of clinical trails

  • dose-response

  • Drug safety and efficacy

  • Data interpretation

Track 6: Pharmacokinetics

Pharmacokinetics is known as what the drug does to body, from entrance into the body until the exit of all traces. This mechanism is done by mainly four processes; absorption, distribution, metabolism, and excretion. Each process is influenced by the route of administration, function of the organs and the dose of administered drug. Drug clearance is a fundamental concept in pharmacokinetics. Drug clearance is the clearance or elimination of drug from the body.

  • Drug clearance

  • Area under curve

  • Pharmacokinetics models

  • Volume of distribution

  • Half-life of drug

Track 7: Pharmacodynamics

Pharmacodynamics, the branch of pharmacology, is known as what the drug does to the body. It deals with the course of action, effect, and breakdown of drugs within the body. The drugs interact with receptors to form therapeutic or toxic effects in the body; this is the pharmacodynamic phase of drug action. By many processes drugs show their effects like by chemical reaction, act on enzyme, act on receptor, by physical action, by physicochemical reaction.

Track 8: Pharmacovigilanace        

Pharmacovigilance is the science and activities which relates to some processes of adverse effects or any other drug-related problem. The processes are detection, assessment, understanding, and prevention. The main aims of pharmacovigilance are to increase the patient care and patient safety in case of use of medicines; and to organise public health programmes to give informations of risk-benefit profile of medicines to the publics.

  • Adverse drug reaction

  • Adverse event

  • Pharmacovigilance process

  • Drug safety

Track 9: Drug Discovery

In the field of biology, biotechnology and pharmacology, drug discovery is the method of drug discovery or design of drugs. In this process, there are some procedures are present; identification of candidates, synthesis, characterization, screening, and assay for therapeutic efficacy. The drug discovery will begin when compounds shows their effect in the above processes. In past, only by identifying the active ingredient from traditional remedies or others, the drugs have been discovered.

Track 10: Pharmaceutical Formulations

In the field of pharmaceutics, pharmaceutical formulation is the process to produce a final medicinal product by combining different chemical substance and the active drug also. It is characterized by two main things: firstly the product should be stable and secondly there is no problem to accept the product by the patients. There are mainly two types of pharmaceutical formulation: Oral formulation- In this case, the products are of two forms: Tablet form and Capsule form and the patient take the produce orally.Topical medication forms- This includes: Cream, Ointment, Gel, Paste, Powder. Sometimes the productsare given to the patients by injection, known as Parenteral formulations.

  • Route of administration

  • Stages of pharmaceutical formulations

  • Polymorphism

  • Dosage forms

  • Preformulation system

  • Encapsulation

Track 11: Biopharmaceutics

Biopharmaceutics is defined as the study of the interrelationship physical/chemical properties of drug. It also examines the dosage form, duration and intensity of action and effect of the drug.  The drug absorption rate is affected by various factors. Biopharmaceutics is involved in the testing of stability of drug, release of API from dosage form, drug conversion rate in solution, absorption of drug into the systemic circulation.

  • Potency of drug products

  • Applied biopharmaceutics

  • Absorption of drug

  • Bioinformatics

  • Recent technology in biopharmaceutics

Track 12: Contract Research Organizations

A contract research organization or CRO is an organization which provides clinical trial and other research supports for the industries of pharmacy, biotechnology medical device. This type of organization also provides support for government institution, foundations, and universities. This type of organization contracted by another company to lead the company’s trials, duties, and functions.  Well-experienced professionals are present here. The organizations offer preclinical, clinical, and regulatory activities for drug development and commercialization.

  • Pre-clinical trial

  • Clinical trial

  • Types of services provides

  • Quality control

  • Quality assurance

  • Good clinical practice

Track 13: Entrepreneur Investment Meet

An entrepreneur, also known as business visionary is a person who, instead of working as an worker, establishes and runs a little commerce, accepting all the dangers and rewards of the wander. The investment is the encompassing of a put by an unfriendly constrain in arrange to blockade or barricade it. Entrepreneur investment meet is a global platform which mainly connects entrepreneurs, proposers, and investors worldwide.

  • Financial markets

  • Classical and neoclassical economists

  • Research and development efforts

  • Investment strategy

  • Types of financial investment

Track 14: Regulatory Affairs

Regulatory requirements are the item or benefit prerequisites that are forced by an exterior (usually governmental) organization that must be met by each item or benefit beneath the domain of that organization. The regulatory for food, vehicles, finance, must be required. People should take regulatory requirements training.

Track 15: Biowaivers

When invivo bioavailability or bioequivalence studies may be waved, its known as biowaivers. Rather than conducting costly and time consuming in vivo studies, a disintegration test may be embraced as the surrogate premise for the decision as to whether the two pharmaceutical items are identical. The biowaivers are not applicable for locally applied products, non-oral immediate release forms, modified release products. The guideline of biowaivers helps to reduce the risk of bioinquivalence to an acceptable level.

  • Dissolution test

  • Biowaiver extensions for class II and class III drugs

  • Evaluation of drug product

  • Reformulated product

  • Extension potential

Market Analysis of BABE 2019

Generic medicine are the medicines that are prescribed and sold-out beneath the non- proprietary name of their active ingredients or not below the brand or trade name.it is only under the general descriptive name. generic drugs only produced after the patent on a drug expires. Generics drugs are same quality as well as the branded drugs, but it is less expensive due to the lower cost using for the research and development.

The total revenue from drug sales across the UAE stands at $1.2 billion a year (Dh4.4 billion), the Department of Health, Abu Dhabi announced 25 per cent of this was from sale of generic drugs, known as generics in short. The prices of the drug in UAE are very high other than the global markets so it needs to be reduced as soon as possible by using the Generic drugs.

In last decade generic drugs have saved $1.67 trillion in the U.S. health care system and generated $253 billion savings only in 2016. Medicare savings are $77 billion and Medicaid savings are $37.9 billion. Generics dispensed are 89% of prescriptions total drugs cost is 26%. During 2011-2017 CAGR of 13% growth has been witnessed in the generic drug market.

 

The GCC countries, comprised of Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the UAE, make up an integral part of the Middle East's pharmaceutical sector. The gradual lowering of medicine prices within the Gulf region, growing awareness of generic drugs, and increasing insurance coverage within the GCCis shown below. BMI has taken this opportunity to survey the landscape of the generic drugs market in the region and assess the market's growth over the coming years.

 

The global clinical trial market having the probability to reach USD 65.2 billion. Many fields like increase development of clinical trials in international level( called Globalization), development of new treatments such as individual medicine, evolution in technology, and increasing demand for CROs to conduct clinical trials are impacted by the key drivers.

The globalization of clinical trials has prompted increment in interest in development of new product in known countries, positively affecting the general market. By giving them the choice to outsource what they believe is past their center mastery, the accessibility of the huge range of administrations from sedate revelation to post-showcasing reconnaissance has additionally streamlined the life for medium size and little scale pharmaceutical and biotechnological association. For example, Pfizer put 3 CROs working, at present for improving the item portfolio and advancement. According to the association associated with ICON in 2011, Pfizer would protect the merchandise for the preliminaries and studies directed by ICON, consequently enabling the organization to center and further build up its abilities in clinical preliminary outlining.

 

Now-a-days, the chances of disease and incidence of new disease would be increased. So the clinical trial market should be boosted. The overall population has different diseases profile with developing nations having the most different illness profile. For discovering the sponsors, boost of the clinical trial of new and uncommon sickness is required. More number of patients with a particular infection would be the goof feature for biopharmaceutical organizations to show more clinical trial for a disease segment.

Related Conferences

  1. 20th World Conference on Pharmaceutical Chemistry and Drug Design, September 03-05, 2018 Dubai, UAE
  2. 10th Annual Congress on Drug Formulation & Analytical Techniques, September 03 - 04, 2018 Dubai, UAE
  3. 22nd World Congress on Nursing, Pharmacology and Healthcare, September 13-14, 2018 Dubai, UAE
  4. Middle East Pharmacy and Pharmaceutical Conference, September 24-25, 2018 Abu Dhabi,
  5. 27th International Conference on Nanomedicine and Nanoscience, October 15-16, 2018 Abu Dhabi, UAE
  6. 21st World Nanotechnology Congress, October 15-17, 2018 Dubai, UAE
  7. International Conference on Pharmacology and Toxicology, October 18-19, 2018 Dubai, UAE
  8. 8th International Conference on Medicinal and Pharmaceutical Chemistry, October 18-19, 2018 Dubai, UAE
  9. 18th Annual Pharma Middle East Congress, November 05-07, 2018 Abu Dhabi, UAE
  10. World Congress on Bioorganic and Medicinal Chemistry, November 12-13, 2018 Dubai, UAE
  11. International Conference on Biomarkers & Clinical Research, November 22-23, 2018 Bucharest, Romania
  12. 4th International Anaesthesia and Pain Medicine Conference, December 13-15, 2018 Abu Dhabi, UAE
  13. 13th International Conference on Allergy and Clinical Immunology, December 13-14, 2018 Abu Dhabi, UAE
  14. 6th World Congress on Drug Discovery & Toxicology, April 22-23, 2019 Abu Dhabi, UAE
  15. 12th International Conference on Pharmacoepidemiology and Clinical Research, March 18-19, 2019 Abu Dhabi, UAE
  16. 18th International Conference on Pharmaceutics & Novel Drug Delivery Systems, March 18-20, 2019 Dubai, UAE
  17. 10th World Congress on Bioavailability & Bioequivalence, April 08-10, 2019 Abu Dhabi, UAE
  18. World Congress on Nanomedicine and Nanotechnology in Healthcare, May 13-14, 2019 Abu Dhabi, UAE
  19. 5th International Conference on Clinical Pharmacy and Health Care, September 26-27, 2018 San Antonio, Texas, USA
  20. 11th World Congress on Pharmaceutical Sciences, September 28-29, 2018 | Montreal, Canada
  21. 4th International Conference on Drug Discovery and Advanced Drug Delivery Systems & Technologies, October 18-19, 2018 Warsaw, Poland
  22. 13th International Conference on Biopharma and Biotherapeutics, October 24-25, 2018 Boston, Massachusetts, USA
  23. 18th Annual Pharma Middle East Congress, November 05-07, 2018 Abu Dhabi, UAE
  24. 18th Annual Pharmaceutical and Chemical Analysis Congress, November 05-06, 2018 Madrid, Spain
  25. 17th World Congress on Drug Formulation & Drug Delivery, November 08-09, 2018 Auckland, New Zealand
  26. 13th World Congress on Pharmacology and Toxicology, November 14-15, 2018 Melbourne, Australia
  27. 9th Global Experts Meeting on Neuropharmacology, November 15-16, 2018 Berlin, Germany

Related Societies/ Associations

USA Region

  1. Academy of Physicians in Clinical Research (APCR)
  2. American Association for Cancer Research (AACR)
  3. American Federation for Medical Research (AFMR)
  4. American Society for Clinical Investigation (ASCI)
  5. Academy of Managed Care Pharmacy
  6. American Association of Pharmaceutical Scientists
  7. American Association of Colleges of Pharmacy
  8. American College of Chest Physicians
  9. American College of Clinical Pharmacy
  10. American Pharmacists Association
  11. American Society of Consultant Pharmacists
  12. American Society of Health-System Pharmacists
  13. Board of Pharmacy Specialties
  14. College of Psychiatric and Neurologic Pharmacists
  15. Haematology/Oncology Pharmacy Association
  16. National Association of Chain Drug Stores
  17. National Community Pharmacists Association
  18. Society of Critical Care Medicine
  19. Society of Infectious Diseases Pharmacists
  20. Indo- American Pharmaceutical Society
  21. International Pharmaceutical Federation (FIP)
  22. International Pharmaceutical Students' Federation
  23. Canadian Pharmacists Association
  24. Canadian Society of Hospital Pharmacists
  25. American Society for Pharmacy Law
  26. Professional Compounding centres of America
  27. American Society of Pharmacognosy
  28. American Society for Automation in Pharmacy
  29. American Institute of the History of Pharmacy
  30. American College of Clinical Pharmacology
  31. American Association of Pharmacy Technician
  32. American Association of Pharmaceutical Scientists
  33. Canadian Association of Chain Drug Stores
  34. U.S. Food and Drug Administration                

Europe Region

  1. National Pharmacy Association-UK
  2. Pharmaceutical Society of Northern Ireland
  3. Royal Pharmaceutical Society
  4. Norwegian Pharmacy Association
  5. Pharmaceutical Society of Ireland
  6. Danish Association of Pharmaconomists
  7. European Association of Employed Community Pharmacists
  8. Pharmaceutical Group of the European Union
  9. European Society of Clinical Pharmacy
  10. European Federation for Pharmaceutical Sciences
  11. Austrian Pharmaceutical Society
  12. Austrian Federal Board of Pharmacy
  13. Association of Finnish Pharmacies
  14. European Association of Employed Community Pharmacists in Europe (EPhEU)
  15. European Pharmaceutical Union (EPU)
  16. Pharmaceutical Group of the European Union (PGEU)
  17. National Pharmacy Association
  18. Royal Pharmaceutical Society (RPS)
  19. German Pharmaceutical Society
  20. The French Pharmaceutical Companies Association
  21. Spanish Society of Hospital Pharmacists
  22. Italian Pharmaceutical Association
  23. Spanish Association of Pharmaceutical Industry
  24. The Association of the British Pharmaceutical Industry
  25. The National Pharmacy Association (NPA)
  26. British Generic Manufacturers Association
  27. Swiss Association of Pharmaceutical Professionals
  28. Hellenic Association of Pharmaceutical Companies
  29. Royal Dutch Pharmaceutical Students'‚Äč Association (KNPSV)
  30. Polish Pharmaceutical Students' Association
  31. Austrian Association of Hospital Pharmacists
  32. Association of Clinical Research Organizations in the Netherlands (ACRON)
  33. Association for Clinical Data Management (ACDM)
  34. Association of CROs Czech Republic (ACRO-CZ)
  35. European Clinical Research Infrastructures Network (ECRIN)
  36. European Society for Clinical Investigation (ESCI)

Middle East Region

  1. Saudi pharmaceutical society
  2. Pharmaceutical Society of Egypt
  3. Egyptian Society of Pharmacology and Experimental Therapeutics
  4. Iranian Society of Clinical Pharmacist
  5. Pharmaceutical Association of Israel
  6. Iranian Association of Pharmaceutical Scientists (IASP)
  7. Pharmaceutical Manufacturers Association of Turkey
  8. Iraq Pharmaceutical Association
  9. Lebanese Pharmaceuticals Importers Association
  10. Jordan Pharmaceutical Association
  11. Jordanian Association of Pharmaceutical Manufacturers
  12. Oman Pharmaceutical Society

Asia-Pacific Region

  1. Pharmaceutical Society of Australia
  2. The Pharmacy Guild of Australia
  3. The Society of Hospital Pharmacists of Australia
  4. Chinese Pharmaceutical Association
  5. Indian Pharmacist Association
  6. Korean Pharmaceutical Association (KPA)
  7. Indian Pharmacological Society
  8. Japan Pharmaceutical Manufacturers Association(JPMA)
  9. Japan Pharmaceutical Association
  10. Vietnamese Pharmaceutical Association
  11. Vietnam Pharmaceutical Companies Association
  12. Pharmaceutical Society of Singapore
  13. (SAPI)Singapore Association of Pharmaceutical Industries
  14. Thai Pharmaceutical Manufacturers Association
  15. Pharmaceutical Research & Manufacturers Association (PReMA)
  16. Pharmaceutical Association of Thailand
  17. The Pharmaceutical Society of Hong Kong
  18. Pakistan Pharmacist Association
  19. Indian Council of Medical Research (ICMR)
  20. Japan CRO Association (JCROA)
  21. Pan-Asian Clinical Research Association (PACRA)
  22. Central Society for Clinical and Translational Research (CSCTR)
  23. Indian Society for Clinical Research (ISCR)
  24. Clinical research society (CRS)

Past Conference Report

BABE 2018

Our sincere thanks to all the speakers and participants of BABE 2018 for their wonderful support.

The 9th world congress on Bioavailability and Bioequivalence which was held during April 16-18, 2018 at JW Marriott Dubai with the theme of “Unfolding Innovations in Bioequivalence/Bioavailability and Related Science” which got a breathtaking response. With the support of the organizing committee members, editorial board members and impressive presentations of all participants this conference became magnificent.

The speakers from different places of the world have given the multiple presentations on the major session like Bioavailability Studies and Assessment, Bioequivalence Studies and Assessment, Pharmacology- PK & PD Approach, Clinical Research vs Clinical Trails, BCS & IVIVC Based Biowaivers, Drug Safety: Pharmacovigilance Scope.

BABE 2018 would like to convey the great appreciation for Dr. Aleksander Mendyk from Jagiellonian University Medical College, Poland for moderating the event and to Dr. Xiaodong Wang from TESARO Inc., USA, Dr. Fatah Kashanchi from George Mason University , USA & Dr. Ranendra N Saha from Birla Institute of Technology and Science-Pilani, India as Keynote seakers.

BABE 2018 would also like to thank the Sunil Kumar Dubey from Birla Institute of Technology and Science-Pilani, India and Aleksander Mendyk from Jagiellonian University Medical College, Poland, Maligne Guillermo E  from Gador S.A., Argentina, Naglaa Gamil Shehab    from Dubai Pharmacy College, UAE, Asmita Gajbhiye Patil from Dr. Harisingh Gour Central University, India, Rajeev Taliyan from Birla Institute of Technology and Science-Pilani, India, Heyam Saad Ali from Dubai Pharmacy College, UAE, Ahmed Ahmed from Northampton General Hospital, UK, Aliasgar Shahiwala from Dubai Pharmacy College, UAE for their sumptuous presentations on their research. Also, it would be incomplete without thanking all our Organizing committee members namely Xiaodong Wang from TESARO Inc., USA and Heyam Saad Ali from Dubai Pharmacy College, UAE who supported us throughout the event.

With the grand success of the 9th world congress on Bioavailability and Bioequivalence we are so excited to announce our upcoming event in the series i.e., 10th world congress on Bioavailability and Bioequivalence during April 08-10, 2019 at Abu Dhabi, UAE.


Past Reports  Gallery  

BABE 2017
We would like to thank all of our wonderful speakers, conference attendees, students, associations and delegates for making BABE 2017 a wonderful event!

8th World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit  hosted by the Conference Series was held during June 26-27, 2017 at  San Diego, California, USA at Hilton San Diego Mission Valley with the theme “Throwing Light on Latest Techniques for Optimization of Drug Solubility, Delivery and Stability for Maximization of Product Life Cycles”, which got magnificent response. With the support and guidance of Organizing Committee Members, Editorial Board Members and astonishing presentations of all participants this prominent summit became more impressive.

We received active participation from various scientists, researchers, students and leaders from the field of Pharmaceuticals who made this event successful.

Conference Series would like to convey a great appreciation to Dr. Palmer Taylor & Dr. Pradeep Kakarla as Keynote speakers and Dr. Sudheendra K. for moderating the event.

Keynote Speaker supported this event with sustainable excitement for grand success of this prominent conference. We are expecting to meet the attendees once again at another part of the world for some other pharmaceutical conference.


Past Reports  Gallery  

BABE 2016

Our Cordial thanks to all of our wondrous and famed speakers, conference attendees, students, associations and guests for shaping BABE 2016 an ineradicable event and a mile stone.

Conference Series hosted the 7th World Congress on Bioavailability and Bioequivalence: BA/BE Studies Summit during August 29-31, 2016 at Atlanta, USA. The conference was designed around the theme of “Amalgamation of traditional techniques to advanced studies which redefine BA/BE approach and perception” and was a great success where eminent keynote speakers from various reputed companies made their resplendent presence and addressed the gathering. Moreover, the networking sessions laid the foundation for some time worthy collaborations between many start-up and big industries. The post conference networking lunch session witnessed a number of B2B meetings that are turning up to be mutually beneficial to both the organizations who had gone in for the business meetings.

BABE 2016 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the field of Bioavailability and Bioequivalence. This congress not only brought forward the latest developments in the field but also provided solutions to the numerous challenges encountered in generic drug sector.

Conference Series would like to convey a warm gratitude to all the Honourable guests, Keynote Speakers, Delegates, Media Partners and Exhibitors for their participation in BABE 2016. The conference was initiated with a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The list includes:

·         Jim Jingjun Huang, Ascendia Pharmaceuticals, USA      

·         Mewa Singh, Meda Biotech LLC, USA

·         Akwete Lex Adjei, Rhodes Pharmaceuticals L.P, USA

 
We on behalf of the conference specially thank Kateryna Zupanets for her support as a moderator for the conference. We also thank Sue Duran, Auburn University, USA and Muneesh Garg, Sitec Labs, India for their support for success of the conference. Conference Series also took the privilege of felicitating BABE 2016 Organizing Committee, Keynote Speakers, and Chair and Co-Chairs whose support made conference a great success with various sessions and multiple presentations.


Past Reports  Gallery  

BABE-2015
We would like to thank all of our wonderful speakers, conference attendees, students, associations and guests for making BABE-2015 a wonderful event!

BABE-2015 which was scheduled during August 17-19, 2015 at Chicago, USA with the theme “Advance Approaches in Discussion of Current Issues & Future Possibilities in Bioavailability and Bioequivalence Studies”. The conference had several workshops, multiple sessions, Keynote presentations, panel discussions and Poster sessions. We received active participation from various leaders from the fields  of Bioavailability and Bioequivalence Research Centres, Professors, Companies, Researchers, students and Research Professionals, who made this event a Grand Success.

Various sessions were carried out with multiple presentations from speakers all around the world. Major Sessions to be discussed were:

·         Emerging Bioavailability and Bioequivalence Studies

·         Bioanalytival Methodology

·         Contempory challenges of drugdesign ,discovery and development

·         Regulatory policies procedures prerequisites for clinical research

·         Managing BA/BE studies

·         Relevance of Genetics to BA/BE in Drug Development

·         Bioavailability, Bioequivalence and Drug Product Selection

·         Advances in Assessment of Bioequivalence

·         Need for conducting  BA/BE studies

·         Metabolic Pathways and Changes in Nutrient Bioavailability

·         Clinical Pharmacology and Therapeutics

·         Study Designs

·         Factors Affecting Bioavailability

The conference was initiated with a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The list includes:

  • Paramjeet Kaur, U.S. Food and Drug Administration, USA
  • Jim Jingjun Huang, Ascendia Pharmaceuticals, USA
  • Keith Gallicano, Novum Pharmaceutical Research Services, USA

Series of workshops includes expert presentation by Paramjeet Kaur, U.S. Food and Drug Administration, USA, on “Biowaiver approaches for generic drug products in the US: case studies”, Jim Jingjun Huang, Ascendia Pharmaceuticals, USA on “Rational design of amorphous solid dispersion for solubility and bioavailability enhancement”, Keith Gallicano, Novum Pharmaceutical Research Services, USA on “Bioequivalence of topical corticosteroids: Design and data analysis challenges with the vasoconstrictor assay”. We specially thank Murat Sari, Pharmactive, Turkey, for his support as a moderator for the conference. We also thank Subrata Deb, Roosevelt University College of Pharmacy, USA for his support for success of the conference.

OMICS International offers its heartfelt appreciation to the Organizing Committee Members, namely Harish Pant, G. Ali Mansoori, A. M. Abd El-Aty, Sachin S Devi who supported us throughout the event. Also, it would be incomplete without thanking all our expert presenters from all around the world which includes various outside experts, company representatives and other eminent personalities who supported the conference by facilitating the discussion forums.

With the grand success of BABE-2015, OMICS International is proud to announce the “7th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit " to be held during August 29-31, 2016 at Atlanta, USA.


Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date April 08-10, 2019

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Past Conference Report

Supported By

Journal of Bioequivalence & Bioavailability Journal of Bioanalysis & Biomedicine Pharmaceutica Analytica Acta

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by


Keytopics

  • Advances In Bioavailability
  • Advances In Pharmaceutical Analytical Methods
  • Analytical Biochemical Techniques
  • Analytical Chemistry
  • Analytical Chromatography
  • Analytical Techniques
  • Anthropology Biomedicine
  • Anvisa Bioequivalence
  • Applied Biomedicine
  • BA/BE Studies
  • Bioanalysis
  • Bioanalysis Methods
  • Bioanalytical Chemistry
  • Bioanalytical Method Validation
  • Bioanalytical Techniques
  • Bioequivalence Anticancers
  • Bioequivalence Antidiabetics
  • Bioequivalence Antidiuretics
  • Bioequivalence Antipsychotics
  • Bioequivalence Cardiovascular Products
  • Bioequivalence Study Design
  • Bioequivalence Study Protocols
  • Biomedical Chromatography
  • Biomedicine And Pharmacotherapy
  • Biopharmaceutics
  • Biosimilars
  • British Regulatory Guidelines
  • Chemical Analysis
  • Chromatographic Techniques
  • Chromatography
  • Clinical Cancer Trials
  • Clinical Drug Trial
  • Competitive Analysis Of Drugs
  • Computational Biomedicine
  • Drug Analysis
  • Drug Delivery Using Nanotechnology
  • Drug Designing
  • Drug Devices
  • European Bioequivalence
  • Experimental Drug Trial
  • FDA Bioequivalence
  • Fragment Based Drug Design
  • GC-MS
  • HPLC
  • HPTLC
  • In Vitro Bioequivalence
  • LC-MS
  • Nanomedicals
  • Paid Clinical Trials
  • Peptidomimetic
  • Pharmaceutical Analysis
  • Pharmaceutical Analytical Market
  • Pharmaceutical Analytical Techniques
  • Pharmaceutical Care
  • Pharmaceutical Companies And Regulatory Guidelines
  • Pharmaceutical Ethics
  • Pharmaceutical Formulation
  • Pharmaceutical Technology
  • Pharmaceutics
  • Product Analysis And Marketing
  • Protease Substrate/Inhibitor
  • Qualitative Analysis
  • Quality Assurance In Pharmaceutical Analysis
  • Quality Assurance In Regulatory Affairs
  • Regulatory Affairs For Clinical Trails
  • Regulatory Compliance
  • Regulatory Consulting And Market Analysis
  • Regulatory Requirements In Bioequivalence
  • Regulatory Requirements Of Pharmaceutical Products
  • Regulatory Services And Market Analysis
  • Screening And Drug Design
  • Spectrometry
  • Structure Based Drug Design
  • US FDA Guidelines